Chemodex

Bicalutamide

As low as CHF 155.00
In stock
Only %1 left
CDX-B0305-G0011 gCHF 155.00
CDX-B0305-GG252.5 gCHF 309.00
NEW
 
More Information
Product Details
Synonyms ICI 176334; ZD 176334; Casodex; Cosudex; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
Product Type Chemical
Properties
Formula C18H14F4N2O4S
MW 430.37
CAS 90357-06-5
RTECS TX1413500
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMF (20 mg/ml) or DMSO (10 mg/ml). Slightly soluble in ethanol (1 mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key LKJPYSCBVHEWIU-UHFFFAOYSA-N
Smiles O=C(C(C)(O)CS(=O)(C1=CC=C(F)C=C1)=O)NC2=CC(C(F)(F)F)=C(C#N)C=C2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description
Bicalutamide is a potent, non-steroidal anti-androgen that functions as a selective androgen receptor (AR) antagonist, widely used in prostate cancer research and studies involving androgen signaling. It binds competitively to the androgen receptor with high affinity, blocking the action of endogenous androgens such as testosterone and dihydrotestosterone, effectively suppressing androgen-driven cellular processes. Bicalutamide is active in both in vitro and in vivo models and demonstrates good oral bioavailability and metabolic stability. Bicalutamide is frequently used to examine the role of androgen receptor inactivation in the proliferation of prostate cancer cells and has served as a molecular template for the design and structural optimization of more selective androgen receptor modulators for androgen therapy.
Product References
(1) S.N. Freeman, et al.; Br. J. Cancer 60, 664 (1989) | (2) D. Masiello, et al.; J. Biol. Chem. 277, 26321 (2002) | (3) D. Yin, et al.; Mol. Pharmacol. 63, 211 (2003) | (4) C.E. Bohl, et al.; PNAS 102, 6201 (2005) | (5) W. Gao, et al.; Pharmacol. Res. 23, 1641 (2006) | (6) C.N. Sternberg; Nat. Clin. Pract. Urol. 3, 408 (2006) | (7) C. Festuccia, et al.; Prostate 67, 1255 (2007) | (8) D.J. Osguthorpe & A.T. Hagler; Biochemistry 50, 4105 (2011) | (9) N.S. Nourbakhsh, et al.; Tissue Cell 91, 102530 (2024)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.